Roswell Park Cancer Institute made national headlines last April in securing an agreement to bring Cuba’s encouraging lung cancer vaccine, CimaVax, to the United States for clinical testing. Nearly one year later, Cuba is back in the news and CimaVax is receiving renewed attention. One of the most frequently asked questions about this vaccine is, “When will it be available for lung cancer patients in the U.S.?”
After completing his fellowship in 2007, Sai Yendamuri, MD, sought a position allowing him to provide care for lung cancer patients while freely collaborating with fellow physicians and oncologists. The multidisciplinary environment at Roswell Park turned out to be exactly what he was looking for.
Betsy Bodie, MSN, RN, NP, and Sabrina Miller, BA, Clinical Liaison, share six common questions and answers about Roswell Park’s Lung Cancer Screening Program that you, and anyone in your life who may be at high risk for lung cancer, need to know.
Roswell Park’s Lung Cancer Screening Program for people at high risk for developing lung cancer includes a focused medical history, physical exam, and helical Low Dose CT (LDCT) chest scan. The LDCT is the only screening test proven to reduce lung cancer deaths.
“I didn’t think I was going to make it, so it’s really about my life today and how cancer makes a difference in a person’s life,” said Thomasina Holmes, a thriving lung cancer survivor who credits Roswell Park Cancer Institute for saving her life.